COMPLIANCE POLICY GUIDE (CPG)
CPG Sec. 220.100 - IS Shipment Biologicals for Medical Emergency August 2000
This CPG concerns the interstate shipment of biological products for use in medical emergencies. It is intended for FDA personnel and also may be used by industry. The CPG does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both.
BACKGROUND: The introduction or delivery for introduction into interstate commerce of a biological product is prohibited unless there is a biologics license in effect for the product, pursuant to Section 351 of the Public Health Service Act.
Occasionally, when a medical emergency arises, an establishment may be requested to ship an unlicensed blood product interstate.
Unscheduled and infrequent interstate shipments of blood products for use in medical emergencies, for which documentation is maintained and made available for Agency examination, do not ordinarily constitute the types of transactions that would require licensure.
The Agency reserves the right to review the documentation relating to such incidents on an individual basis, to prevent the interstate shipment of unlicensed blood products under the guise of responding to a medical emergency. Such documentation must be maintained at the establishment that ships the product in response to the emergency.
If, after thorough review of all documentation and other pertinent information, the Agency determines that the incident was an attempt to circumvent the regulations, regulatory action should be considered.
Issued: 12/1/77 as 7134.12 (sic)
Revised: 10/1/80, 3/95, 8/2000
Hypertext created 2/20/2001 tc
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.